NovaGo Therapeutics AG, a Zurich, Switzerland-based biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, closed a Series A financing round of CHF 10m.
The round was led by Pureos Bioventures and the strategic partner Neurimmune. In conjunction with the funding, Dr. Dominik Escher, Partner at Pureos Bioventures, will join NovaGo’s board of directors.
The company intends to use the proceeds to develop its regenerative therapeutics towards clinical trials.
Founded 2015 as a spin-off company from the University of Zurich and led by Prof. Martin E. Schwab, founder and President, and Dr. Eduardo Vianna, CEO, NovaGo Therapeutics is dedicated to the development of regenerative therapies for diseases of the central nervous system such as stroke and spinal cord injury.
The company previously entered into a strategic partnership with Neurimmune, a Swiss clinical stage biotech company translating human immune memory into game changing therapeutics, to discover human antibodies targeting Nogo-A. Neurimmune’s Reverse Translational Medicine™ technology decodes genetic information of immune cells obtained from healthy aged people to identify next generation antibody therapeutics.